Orfiril (Sodium Valproate)

Sodium valproate enhances the inhibitory neurotransmitter GABA by inhibiting its breakdown and increasing its synthesis. It also blocks voltage‑gated sodium channels and modulates calcium currents, which together reduce neuronal hyperexcitability and help control seizures, mood swings, and migraine pathways.

The dosage of Orfiril is individualized and determined by a qualified prescriber based on the patient’s age, weight, clinical condition, and response to therapy. Physicians adjust the dose to achieve optimal seizure control or mood stabilization while monitoring for safety.

Orfiril is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be used only when the potential benefits justify the risks. Sodium valproate is excreted in breast milk, so breastfeeding decisions should be made in consultation with a healthcare professional.

To request Orfiril, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Compared with alternatives such as carbamazepine or lamotrigine, sodium valproate offers broad-spectrum seizure control and mood‑stabilizing properties but carries a higher risk of hepatic and metabolic side effects. Choice of therapy depends on the specific seizure type, patient comorbidities, and tolerance to potential adverse effects.

Orfiril should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store it in areas with high humidity or extreme heat.

Orfiril is taken orally, usually as a tablet or capsule, and should be swallowed whole with a glass of water. Doses are typically divided throughout the day as prescribed, and it may be taken with or without food depending on the prescriber’s instructions.

The most serious risks include severe liver injury, acute pancreatitis, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and hematologic abnormalities like thrombocytopenia. Patients should be monitored regularly for signs of hepatic dysfunction, abdominal pain, rash, or unexplained bruising.

Orfiril is contraindicated in individuals with known hypersensitivity to sodium valproate, those with urea cycle disorders, mitochondrial diseases, or severe hepatic impairment. It should also be avoided in pregnant women unless no safer alternative exists and the therapeutic benefit outweighs fetal risk.